AUS
NZ
UK
CA
USA
IND
_06_04_2026_00_29_48_108019.jpg)
Clinical-stage Australian drug development company, Noxopharm Limited (ASX: NOX) has released an interview with Associate Professor Louise Emmett who is the co-Principal Investigator of the LuPIN-1 Study which is being conducted at St Vincentâs Hospital, Sydney. Following the release of the interview, the share price of the company increased by 15 percent as on 14 January 2019.
LuPIN-1 study was initiated by the academic team led by Dr. Emmett and this study is being conducted on men with late-stage prostate cancer. The LuPIN-1 study involves a combination therapy of Veyonda and an experimental radiopharmaceutical drug, 177lutetium-PSMA-617 (Lu-PSMA) and the goal behind combining both these drugs is to raise the response rate by boosting the anticancer benefit of Lu-PSMA without causing unacceptable increases in side-effects. Till now, the combination treatment has proven to be well tolerated, consistent with other clinical studies using Veyonda where there has been a lack of any dose-limiting toxicity. The efficacy of the drugs is measured through PSA responses, pain reduction, and through the proportion of men who complete their full treatment course, and time to disease progression.
Till now, the Lu-PSMA therapy has been used in more than 3000 men, and although it is considered very promising, its effectiveness is limited by a number of factors such as the amount of lutetium taken up by each cancer cell. In LuPIN-1 study, the company is currently targeting to increase the number of men who will be able to complete their full six cycles of treatment. Further, the company is targeting greater depth of response, i.e. more than 90 percent reduction in PSA levels.
As per the companyâs Chief Medical Officer Dr. Greg van Wyk, the company has entered into discussions with its partners about starting the next stage of the LuPIN program. In the phase 2 of this study, the company will be aiming to show a definitive survival advantage compared to Lu-PSMA treatment alone.
Dr. Greg van Wyk also informed about the companyâs DARRT program in which the company is studying the use of Veyonda to increase the anti-cancer effect of externally delivered radiotherapy. In both the program, the company is focusing on prostate cancer, but this year the company is accelerating its efforts to study Veyonda in sarcomas, where Veyonda will be used in combination with radiotherapy or chemotherapy.
Meanwhile, in the last six months, the share price of the company decreased by 31.03 percent as on 11 January 2019. NOXâs shares traded at $0.460 with a market capitalization of circa $48.87 million as on 14 January 2019 (AEST 4:00 PM).
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
